Subsequently, PD-L1 CPS and CD8+ TIL densities were combined to categorize the immune response to the tumor into four subtypes, as described by Teng et al. [23]: positive PD-L1 CPS /high CD8+ TIL density (type I, adaptive immune resistance) was observed in 15/64 cases (23%); negative PD-L1 CPS /low CD8+ TIL (type II, immunological ignorance) in 24/64 cases (37%); positive PD-L1 CPS /low CD8+ TIL (type III, intrinsic induction) in 20/64 cases (31%); and negative PD-L1 CPS /high CD8+ TIL (type IV, immune tolerance) in 5/64 cases (8%). The gene discussed is CD8A; the disease is neoplasm.